Form 4: Incyte EVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, sold 5,808 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.
Summary
- Patrick A. Mayes, Executive Vice President and Chief Scientific Officer of Incyte Corp (INCY), reported transactions involving the sale of common stock.
- On December 10, 2025, Mr. Mayes sold 5,553 shares of Incyte common stock at a price of $95.58 per share.
- On December 11, 2025, an additional 255 shares were sold at a price of $94.94 per share.
- These transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
- Following these sales, Mr. Mayes beneficially owns 60,011 shares of Incyte common stock.
- The beneficial ownership includes 59,858 shares of common stock issuable from previously reported restricted stock units that have not yet vested.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the reported sales were conducted under a Rule 10b5-1 plan, indicating pre-scheduled transactions rather than a discretionary sale based on new material information.
Negatives
- An executive, Patrick A. Mayes, sold a total of 5,808 shares of company common stock over two days.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction report is a routine disclosure required by the SEC and does not inherently provide insight into broader industry trends or competitive landscape. It reflects an individual executive's stock activity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure of Trading Plan | The reported transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | N/A | The use of a Rule 10b5-1 plan enhances transparency and provides an affirmative defense against insider trading allegations by demonstrating that trades were pre-scheduled when the insider was not in possession of material non-public information. |
Stakeholder Impact
- Shareholders: The sale by a key executive represents a minor reduction in insider ownership, which is a routine event when conducted under a 10b5-1 plan and is unlikely to significantly impact shareholder sentiment or company strategy.
Key Dates
| Date | Description |
|---|---|
| 12/10/2025 | Transaction date for the sale of 5,553 shares of common stock. |
| 12/11/2025 | Transaction date for the sale of 255 shares of common stock. |
| 12/12/2025 | Date the Form 4 was signed and filed. |
Keywords
Incyte, INCY, insider trading, Form 4, stock sale, executive compensation, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.